Hepan

Hepan is a prescription injectable product that combines heparin sodium and dexpanthenol in a solution for subcutaneous administration. While specific strength and concentration are not disclosed, the formulation is intended for use in the European market. Heparin sodium provides anticoagulant activity, and dexpanthenol serves as a provitamin B5 that supports cellular metabolism and skin repair. The product is supplied as a sterile liquid for injection.

Hepan is used in clinical practice where anticoagulation and local tissue support are required, particularly in settings that involve subcutaneous injections and may be considered as part of peri‑procedural protocols. - Prevention of clot formation in patients requiring short‑term anticoagulation during minor surgical or diagnostic procedures. - Management of catheter‑related thrombosis risk when a subcutaneous route is preferred. - Adjunctive therapy to support skin integrity and wound healing in patients with compromised tissue repair. - Use in patients with a need for both anticoagulant effect and topical skin benefit, such as after subcutaneous injections. - Situational use in prophylaxis of venous thromboembolism where oral anticoagulants are contraindicated.

The safety profile of Hepan reflects the combined actions of heparin sodium and dexpanthenol, with side effects ranging from mild to potentially serious.

Common: - Minor injection‑site reactions such as erythema, mild swelling, or tenderness that resolve spontaneously. - Small bruising or localized hematoma at the site of subcutaneous administration. - Transient headache or dizziness that does not require medical treatment. - Slight prolongation of bleeding time without clinically evident hemorrhage.

Serious: - Significant bleeding or hemorrhage, including gastrointestinal, intracranial, or severe mucosal bleeding. - Development of thrombocytopenia or heparin‑induced thrombocytopenia (HIT) with a notable drop in platelet count. - Allergic reactions ranging from urticaria and pruritus to full‑body anaphylaxis. - Marked elevation of liver enzymes suggesting hepatic stress or injury.

When prescribing Hepan, clinicians should evaluate patient history and monitor for conditions that could increase the risk of adverse events or reduce therapeutic benefit. - Assess bleeding risk, including recent surgery, trauma, or known coagulopathies before initiating therapy. - Review renal and hepatic function, as impairment may affect drug clearance and safety. - Use caution in pregnant or lactating individuals; safety data are limited. - Avoid concurrent use with other parenteral anticoagulants unless specifically indicated. - Monitor platelet counts regularly to detect possible heparin‑induced thrombocytopenia. - Observe injection sites for signs of infection or persistent inflammation.

Hepan may interact with other medications that affect coagulation, platelet function, or hepatic metabolism, requiring careful review of the patient’s drug regimen.

Avoid: - Concomitant use of other injectable anticoagulants such as unfractionated heparin or low‑molecular‑weight heparins. - Simultaneous administration of thrombolytic agents (e.g., alteplase, streptokinase) that markedly increase bleeding risk. - Combination with antiplatelet drugs (e.g., clopidogrel, ticagrelor) when high bleeding potential is present.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which may modestly prolong bleeding time. - Medications metabolized by the liver (e.g., certain antibiotics, antifungals) that could alter dexpanthenol conversion. - Herbal supplements such as ginkgo biloba or garlic that possess mild anticoagulant properties.